Lypozik CF
Natural health product licensed in Canada
- Licence holder
- Distributions Santé Leblanc
- NPN or DIN-HM
- 80038338
- Status
- Active licence
- Licence date
- 17 December 2012
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Amorphophallus konjac Source : Racine | 145 mg | Not calculated |
| Opuntia streptacantha Source : Cactus Extraction ratio : 5:1 Dry plant equivalent : 25 mg | 5 mg | Not calculated |
Non-medicinal ingredients
Gélatine, Stéarate de magnésium
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 2 Capsule | 1 Tous les jours |
Uses authorised in Canada
Lypozik CF est utilisé dans le cadre d'un programme qui recommande une réduction de l'apport calorique et une augmentation de l'activité physique (dans la mesure du possible) pour aider à la gestion du poids.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Contre-indications
Ne consommez pas ce produit si vous avez de la difficulté à avaler. Ne pas prendre si vous êtes enceinte ou si vous allaitez.
Source
Official Health Canada record, licence 80038338
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.